Search

Search Constraints

You searched for: Author/Creator Sun, Steven

Search Results

11. Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR. Issue 10 (1st April 2021)

12. Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Issue 13 (9th November 2020)

13. Hepatic angiomyolipoma: an international multicenter analysis on diagnosis, management and outcome. Issue 4 (April 2020)

14. Ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone in patients with previously untreated non‐germinal centre B‐cell‐like diffuse large B‐cell lymphoma: A Chinese subgroup analysis of the phase III PHOENIX trial. Issue 4 (30th August 2022)

15. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Issue 2 (February 2016)

16. Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open‐label phase 3 study. (13th March 2018)

17. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Issue 10020 (20th February 2016)

18. Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial. (17th November 2021)

19. Implementation and early outcomes for a surgeon‐directed hepatic arterial infusion pump program for colorectal liver metastases. Issue 7 (30th October 2018)